Voyager Therapeutics (VYGR) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS
Voyager Therapeutics (NASDAQ:VYGR) released its quarterly earnings data on Wednesday. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.15, Fidelity Earnings reports. The firm had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $3.02 million. Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%.
VYGR traded down $1.68 during trading hours on Thursday, hitting $12.31. The company’s stock had a trading volume of 1,322,072 shares, compared to its average volume of 406,743. Voyager Therapeutics has a 12 month low of $11.00 and a 12 month high of $31.91. The stock has a market capitalization of $442.10 million, a PE ratio of -4.66 and a beta of 3.15.
In other Voyager Therapeutics news, Director James A. Geraghty purchased 3,000 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, September 10th. The shares were bought at an average price of $19.39 per share, for a total transaction of $58,170.00. Following the completion of the transaction, the director now owns 76,588 shares of the company’s stock, valued at approximately $1,485,041.32. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glenn Pierce purchased 5,000 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, September 12th. The stock was acquired at an average price of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. Insiders purchased 11,000 shares of company stock worth $205,300 in the last 90 days. 33.60% of the stock is currently owned by company insiders.
Several equities research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 25th. Canaccord Genuity reiterated a “buy” rating and set a $31.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, July 17th. Morgan Stanley cut shares of Voyager Therapeutics from an “overweight” rating to an “equal” rating in a research report on Monday, September 10th. BTIG Research reiterated a “buy” rating and set a $32.00 price objective on shares of Voyager Therapeutics in a research report on Monday, September 10th. Finally, HC Wainwright set a $30.00 price objective on shares of Voyager Therapeutics and gave the company a “buy” rating in a research report on Tuesday, July 17th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Voyager Therapeutics currently has a consensus rating of “Buy” and an average target price of $28.56.
COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/11/08/voyager-therapeutics-vygr-releases-quarterly-earnings-results-beats-expectations-by-0-15-eps.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Recommended Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.